President Donald Trump is expected to sign an executive order aimed at expanding U.S. research into ibogaine, a psychedelic compound that some clinics abroad use to treat post-traumatic stress disorder, traumatic brain injury, addiction, depression, and anxiety.
CBS News reported that the White House is drafting an order meant to encourage deeper federal study of the drug, particularly for veterans, while stopping short of reclassifying it for medical use in the United States. Ibogaine would remain a Schedule I substance under federal law.
